1.00
-0.02(-1.96%)
Currency In USD
| Previous Close | 1.02 |
| Open | 1.06 |
| Day High | 1.06 |
| Day Low | 1 |
| 52-Week High | 1.59 |
| 52-Week Low | 0.77 |
| Volume | 461,266 |
| Average Volume | 453,600 |
| Market Cap | 100M |
| PE | -3.33 |
| EPS | -0.3 |
| Moving Average 50 Days | 1.01 |
| Moving Average 200 Days | 1.14 |
| Change | -0.02 |
If you invested $1000 in Cardiol Therapeutics Inc. (CRDL) since IPO date, it would be worth $267.27 as of February 21, 2026 at a share price of $1. Whereas If you bought $1000 worth of Cardiol Therapeutics Inc. (CRDL) shares 5 years ago, it would be worth $273.22 as of February 21, 2026 at a share price of $1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Newsfile
Feb 10, 2026 12:27 PM GMT
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Newsfile
Jan 23, 2026 2:16 PM GMT
Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Newsfile
Jan 16, 2026 1:46 PM GMT
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic